China robotics surgical market to escalate to 12% through 2033

The market requires advanced tech as its mortality rates rise.

China said it is experiencing a rise in the adoption of robotic systems across different healthcare domains as the demand for advanced tech in healthcare rises, said GlobalData.

"Against this backdrop, the robotic surgical systems market in China is expected to grow at a compound annual growth rate of around 12% between 2023 and 2033, forecasts GlobalData, a leading data and analytics company," said the data and analytics firm.

The market accounts for about 30% of the APAC robotic surgical systems market in 2023.

One example of this growth is Johnson & Johnson's Monarch Platform and Monarch Bronchoscope, a robotically assisted device, which have received regulatory approval in China.

Diksha Balmuchu, Medical Devices Analyst at GlobalData, said China's rising mortality rates may have emphasised the urgent need for more advanced, less invasive, and precise interventions, prompting a shift towards robotic-assisted interventions.

“China continues to make steady progress in the research and healthcare domain, advancing towards the integration of robotic-assisted technology. Monarch, one such technology with its promising results, has the potential to alleviate diseases, reducing the risk of mortality and facilitating timely treatment in China," added Balmuchu.